Immune response to a mammary adenocarcinoma. V. Sera from tumor-bearing rats contain multiple factors blocking cell-mediated cytotoxicity.
Sera from Fischer rats 3 to 13 days after i.p. injection of syngeneic 13762A mammary adenocarcinoma contain three factors specifically blocking cell-mediated cytotoxicity (CMC). The major blocking factor is a 160,000-dalton IgG that combines specifically to cytolytic lymphocytes but not to tumor cells or tumor antigen, and that is not dissociated after treatment with 8 M urea. The other factors have been putatively identified as tumor antigen (less than 70,000 daltons) and as soluble antigen-antibody complexes (greater than 200,000 daltons). Injecting the tumor antigen into tumor-free rats induced spleen cells specifically cytotoxic to the 13762A tumor and provided partial protection to challenge with live tumor cells. Treating soluble antigen-antibody complexes with 8 M urea decreased the size of the blocking activity from greater than 200,000 to less than 70,000 daltons. Although the IgG fraction dissociated from the complex did not block CMC, it did recombine with the tumor antigen fraction to transfer activity to the greater than 200,000-dalton fraction. In contrast, mixing tumor antigen with the IgG fraction that did block CMC did not alter the size of the blocking activities.
D000230:Adenocarcinoma / Q000276:immunology*; D000818:Animals; D000936:Antigen-Antibody Complex; D001667:Binding, Competitive; D002850:Chromatography, Gel; D003602:Cytotoxicity, Immunologic; D005260:Female; D007111:Immunity, Cellular; D007074:Immunoglobulin G; D008325:Mammary Neoplasms, Experimental / Q000276:immunology*; D008970:Molecular Weight; D051381:Rats; D011916:Rats, Inbred F344; D012995:Solubility
D000936:Antigen-Antibody Complex; D007074:Immunoglobulin G